<DOC>
	<DOCNO>NCT00051662</DOCNO>
	<brief_summary>The purpose study determine whether humanized monoclonal antibody ( efalizumab ) safe effective treatment psoriatic arthritis ( PsA )</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetics Antibody Psoriatic Arthritis</brief_title>
	<detailed_description>A phase II , randomize , double-blind , placebo-controlled study : 1 . Demonstrate clinical efficacy efalizumab treatment subject psoriatic arthritis ( PsA ) . 2 . Evaluate safety , tolerability pharmacokinetics efalizumab treatment subject PsA</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Inclusion criterion : Diagnosed PsA define : Presence psoriasis least one 2 cm plaque AND One five functional classification PsA Functional Class I , II , III define ACR Classification Functional Status Rheumatoid Arthritis Moderate severe disease , define follow : At least 3 tender 3 swollen joint ( 78 joint count tenderness 76 joint swell ; AND Either ESR ≥ 28 mm/hr , CRP ≥ 1.5 mg/dL , morning stiffness ≥ 30 minute . Currently take least one follow systemic therapy PsA : preexisting stable dos NSAIDs , corticosteroid ( ≤ 10 mg/day ) , either sulfasalazine ( ≤ 3 gm/day ) methotrexate ( ≥ 7.5 ≤ 30 mg/week ) . 18 80 year age . Body weight ≤ 125 kg ( 275 lb ) . Candidate systemic immunomodulatory therapy . Using acceptable method birth control . If female , must negative serum pregnancy test screening period , must surgically sterile , must least five year postmenopausal . Informed study sign informed consent prior performance studyrelated procedure . Exclusion criterion : Previous treatment efalizumab . Rheumatoid Factor positive without dactylitis positive Xrays hand foot , rheumatoid nodule . History joint replacement surgery within 60 day prior start study drug dose . Joint replacement therapy plan within nine month subsequent start study drug dose . Intraarticular cortisone injection within 28 day prior start study drug dosing . Pregnancy lactation . History severe allergic anaphylactic reaction humanize murine monoclonal antibody . Respiratory distress ( dyspnea , oxygen desaturation pO2 &lt; 90 % onset acute respiratory distress syndrome ) , flank back pain , and/or hypotension may sign anaphylaxis . Active bacterial , viral , fungal , mycobacterium tuberculosis atypical mycobacterium infection . Positive PPD test unless subject positive PPD test complete course treatment tuberculosis History opportunistic infection . History malignancy within past five year . Subjects history fully resolve , resect , basal squamous cell carcinoma may enrol . Received vaccine within 28 day prior start study drug dosing . Chronic disorder apart PsA affect joint , systemic lupus erythematosus , rheumatoid arthritis , gout , scleroderma know reactive arthritis ( e.g. , Reiter ’ syndrome ) . COPD , asthma , pulmonary disease require therapy use one inhaler 4× daily . Failed respond maintain response Enbrel . Received DMARD methotrexate sulfasalazine 28 day prior start study drug dosing . Approved biologic PsA therapy 28 day seven halflives drug prior start study drug dosing , whichever great length time ; Enbrel within 42 day prior start study drug dosing . Investigational drug and/or treatment 28 day 7 halflives drug prior start study drug dosing , whichever great length time . Any condition , opinion Investigator , would jeopardize subject ’ safety follow exposure efalizumab . Liver disease ( e.g. , hepatitis , cirrhosis ) abnormal hepatic function ( AST ALT ≥ 2.5 ULN ) . Serum creatinine level ≥ 1.5 mg/dL Platelet count ≤ 125,000 cells/mm3 WBC count ≤ 3,500 cells/mm3 Total lymphocyte count ≤ 1000 cells/mm3 Seropositive hepatitis B Seropositive hepatitis C antibody Seropositive HIV Antinuclear antibody titer ≥ 1:80 History inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2004</verification_date>
</DOC>